Back to Ticker-Terminal
After hours
NYSE
Healthcare

Eli Lilly & Co. (LLY) stock

Eli Lilly & Co. (LLY) trades on NYSE and is classified in the Healthcare sector. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. This page tracks LLY using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.

LLY stock analysis and research from Ticker-Terminal
$1,380.89$92.59 (+7.19%)Verified · 17 minutes ago

Previous close

$1,288.30

Volume

4,367,088

52-week range

$809.63 – $1,408.38

Market cap

$1.15T

Source: Polygon (snapshot) · Verified Oct 29, 2026, 6:02 PM EDT

Performance

1D

+7.19%

1W

+5.13%

1M

+15.96%

1Y

+68.86%

Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.

Reported financials

Verified · 22 hours ago

Revenue (TTM)

$86.46B

Reported Q3'26 · Polygon (company financials)

Revenue growth (YoY)

38.6%

Reported Q3'26 · Polygon (company financials)

EPS (TTM, diluted)

23.42

Reported Q3'26 · Polygon (company financials)

EPS growth (YoY)

16.3%

Reported Q3'26 · Polygon (company financials)

Gross margin

Data unavailable

Reported Q3'26 · Polygon (company financials)

Operating margin

Data unavailable

Reported Q3'26 · Polygon (company financials)

Net margin

31.9%

Reported Q3'26 · Polygon (company financials)

Operating cash flow (TTM)

$30.64B

Reported Q3'26 · Polygon (company financials)

Revenue 2-year CAGR

40.1%

Reported Q3'26 · Polygon (company financials)

Source: Polygon financials + Finnhub earnings · Latest reported Q3'26 · Verified Oct 28, 2026, 8:00 PM EDT

Valuation

P/E (trailing)

59.0

Reported Q3'26 · Ticker-Terminal (last verified price ÷ TTM diluted EPS)

P/E (forward, est.)

51.2

Ticker-Terminal (last verified price ÷ annualised consensus EPS estimate)

Market cap

$1.15T

Polygon / Finnhub reference

Dividend yield

No dividend currently reported

Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.

Earnings

Verified · 22 hours ago

Next earnings date

Oct 28, 2026

Source: Finnhub earnings calendar

Latest reported quarter

Q3'26

Revenue $24.40B · Diluted EPS 7.22

LLY EPS actual versus estimate by reported period
PeriodEPS actualEstimateSurprise
2026-09-307.486.61+13.1%
2026-06-308.386.07+38.1%
2026-03-318.556.73+27.0%
2025-12-317.546.74+11.9%

Ticker-Terminal analysis of LLY

70/ 100 quality score
C-
Growth18/25
Profitability25/25
Financial strength25/25
Valuation2/25

Earnings-power range

Bear $843.12 · Base $1,053.90 · Bull $1,264.68 — Overvalued versus the last verified price.

Bull case

Sustained growth and margin strength support roughly $1,264.68.

  • Applies a 45× earnings multiple to trailing diluted EPS of 23.42, plus a 20% upside band.
  • Latest reported revenue growth: 38.6% year over year.
  • Operating margin could not be verified.

Base case

Current reported earnings power maps to roughly $1,053.90 (overvalued versus the last verified price).

  • Earnings-power estimate: trailing diluted EPS × a growth-adjusted 45× multiple.
  • Implied difference versus the last verified price: -23.7%.
  • Trailing operating cash flow: $30.64B.

Bear case

Multiple compression or slowing growth maps to roughly $843.12.

  • Applies a 20% downside band to the earnings-power estimate.
  • Latest reported EPS growth: 16.3% year over year.
  • Downside from the last verified price in this scenario: -38.9%.

Calculated from verified reported financials and the last verified price (data verified Oct 29, 2026, 6:02 PM EDT). Analytical model output, not a price target or investment advice.

Analyst consensus

Unavailable

Rating

Buy

Average target

Unavailable

Range

Unavailable

Analysts

36

Source: finnhub

Recent LLY news

Verified · 2 hours ago

Data confidence: Partial confidence

Some data is delayed, stale or unavailable. Everything shown is still verified.

  • 1 financial metric unavailable.

Still fully reliable

Company profile and business overview · Reported financial statements · Earnings history · Ticker-Terminal analysis

Compare This Stock

LLY in its sector

Run full AI research on LLY

This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.

Analyze LLY freeToday's market snapshot

LLY questions, answered

What does Eli Lilly & Co. do?

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Where is LLY listed?

Eli Lilly & Co. trades under the ticker LLY on NYSE.

What is the LLY stock price today?

LLY was last verified at $1,380.89 (7.19% on the day). After hours, last verified Oct 29, 2026, 6:02 PM EDT. Market data may be delayed and is shown with its own timestamp.

Is Eli Lilly & Co. revenue growing?

Based on the latest reported financials, LLY revenue changed 38.6% year over year (filed Oct 28, 2026).

When does Eli Lilly & Co. report earnings next?

The next confirmed LLY earnings date is Oct 28, 2026, per Finnhub earnings calendar. Dates can be revised by the company.

What did Eli Lilly & Co. report in its latest quarter?

For Q3'26, LLY reported revenue of $24.40B and diluted EPS of 7.22.

What is Ticker-Terminal's LLY growth score?

Ticker-Terminal scores LLY at 70/100 (C-) from verified growth, profitability, financial strength and valuation inputs. It is an analytical model based on available verified data, not a guarantee of future performance.

How can I run deeper AI research on LLY?

Create a free Ticker-Terminal account to run a full AI research report on LLY — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.

Learn how to read this

Trading psychologyMarket cyclesAI investing

Free guide series

Get the “how to research a stock” checklist

Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.

  • The 7-step “how to research a stock” checklist, sent immediately
  • The next recommended guide in the series, two days later
  • Occasional new guides only — no daily market noise, unsubscribe in one click

No spam, unsubscribe in one click. Educational information only, not investment advice.

Social Media
Follow us on XFollow us on TikTok

Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from LLY's most recently reported statements and are not restated by Ticker-Terminal.

Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.

See our risk disclosure. Page data assembled Oct 29, 2026, 6:19 PM EDT.